The History and Mission of York Clinical Research
York Clinical Research, LLC is committed to the development of safe and effective pharmaceuticals, biologics, gene modulating agents, and medical devices for the benefit of all mankind. Founded in 2001, York Clinical Research has some 50 past and active clinical trials in its research portfolio and takes pride in having assisted the pharmaceutical industry in introducing many life-saving, and disease modifying drugs into medical therapeutics through clinical research. Our experience ranges from traditional receptor antagonists and agonists to the gene modulating antisense oligonucleotide strategy of translation arrest. We have experience in development phases II through IV. We have collaborated in the development of therapeutic agents of several classes for the treatment of hypertension, type 2 diabetes, and dyslipidemia. We also have conducted clinical trials in congestive heart failure, COPD, asthma, anti-coagulation, arthritis, IBS, and ED. Our study coordinators engage in scheduled continued quality improvement and recertification. All research is conducted in compliance with GCP/ICH.
About Charles F. Lovell, M.D., FACP
Charles Lovell, Jr. was born in Winston-Salem, North Carolina. After completing the ninth grade, his parents sent him to New York to live with an uncle for his remaining high school years. He prepared himself for his future medical career by taking all the math courses offered, studying Russian and French, serving as president of the National Honor Society and graduating with honors. Dr. Lovell was admitted to Harvard College and graduated with an undergraduate degree in biology. He graduated from Columbia University’s medical school in 1972. After serving as chief resident at Harlem Hospital Center, he went to the Atlanta-based Centers for Disease Control and Prevention’s Epidemic Intelligence Service (EIS).
Dr. Lovell moved to Hampton Roads in 1978 to begin an internal medicine practice in Norfolk, Virginia and was also appointed assistant professor of clinical internal medicine at Eastern Virginia Medical School (EVMS). That same year, he discovered that Medicare would not pay for pneumonia vaccines for the elderly but would pay for extended stays if they developed pneumonia and had to be hospitalized. He wrote a letter to the editor of The Virginian-Pilot newspaper to advocate for better and preventive health care for elderly Medicare patients nationwide. He pointed out that it is easier to prevent illnesses than to cure them and that vaccinations save lives and improve people’s quality of life. U.S. Congressman G. William Whitehurst read the letter and worked with Dr. Lovell to enact legislation to include preventive health services as a part of Medicare. As a result, both he and Rep. Whitehurst were awarded the American Lung Association’s Annual Award in 1981.
In 1993, Dr. Lovell became the first African American to serve as president of the Commonwealth of Virginia Board of Medicine. In 2006, his practice was designated a Cardiovascular Center of Excellence by the Consortium for Southeastern Hypertension Control. Dr. Lovell divided his time between his private practice and his medical initiative entitled, the 3 Diseases Project, whose mission is to diagnose and treat hypertension, diabetes and high cholesterol through the utilization of cutting edge technologies. In 2007, Dr. Lovell was an honoree of Dominion Virginia Power’s Strong Men & Women in Virginia History, an annual program which highlights African-American men and women whose accomplishments and determination demonstrate true excellence in leadership.
Dr. Lovell is a former member of the National Vaccine Advisory Committee. He currently serves as assistant professor of clinical medicine at EVMS. He is married to his wife, Barbara, and they have one daughter, Sarah Rachel.